{"id":53729,"date":"2026-01-12T14:31:37","date_gmt":"2026-01-12T06:31:37","guid":{"rendered":"https:\/\/flcube.com\/?p=53729"},"modified":"2026-01-12T14:31:37","modified_gmt":"2026-01-12T06:31:37","slug":"boan-biosimilar-prolia-wins-bolivia-approval-targets-global-markets","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=53729","title":{"rendered":"Boan Biosimilar Prolia Wins Bolivia Approval, Targets Global Markets"},"content":{"rendered":"\n<p><strong>Shandong Boan Biotechnology Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/6955:HKG\">HKG: 6955<\/a>) announced that <strong>BA6101<\/strong>, its <strong>biosimilar version of Amgen\u2019s Prolia (denosumab)<\/strong>, received marketing approval from <strong>Bolivia\u2019s AGEMED<\/strong> (Agencia Estatal de Medicamentos y Tecnolog\u00edas en Salud). The 60mg injection for <strong>osteoporosis<\/strong> marks Boan\u2019s first regulatory approval in <strong>South America<\/strong> and advances its global expansion strategy, with filings already under review in the <strong>UK<\/strong> and planned for <strong>Europe, the US, and Japan<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Product<\/strong><\/td><td>BA6101 (denosumab biosimilar)<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>Shandong Boan Biotechnology (6955.HK)<\/td><\/tr><tr><td><strong>Approval<\/strong><\/td><td>AGEMED (Bolivia)<\/td><\/tr><tr><td><strong>Reference Drug<\/strong><\/td><td>Prolia (Amgen originator)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Bone loss (osteoporosis) in at-risk patients<\/td><\/tr><tr><td><strong>Dosage<\/strong><\/td><td>60mg injection<\/td><\/tr><tr><td><strong>China Approval<\/strong><\/td><td>December\u202f2022 (marketed by BeiGene)<\/td><\/tr><tr><td><strong>Global Strategy<\/strong><\/td><td>UK under review; EU, US, Japan filings planned<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity\">Market Opportunity<\/h2>\n\n\n\n<p><strong>Denosumab Landscape<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Global Sales<\/strong>: <strong>$4.5\u202fbillion<\/strong> (2025), with <strong>Prolia<\/strong> dominating the <strong>RANKL inhibitor<\/strong> market<\/li>\n\n\n\n<li><strong>China Market<\/strong>: <strong>\u00a53.2\u202fbillion<\/strong> (US$450\u202fmillion) and growing at <strong>12% CAGR<\/strong><\/li>\n\n\n\n<li><strong>Biosimilar Wave<\/strong>: <strong>5\u20116<\/strong> denosumab biosimilars in global development; Boan is <strong>first Chinese company<\/strong> to secure <strong>ex\u2011China approval<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Bolivia Opportunity<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Addressable Patients<\/strong>: <strong>~50,000<\/strong> osteoporosis patients eligible for therapy<\/li>\n\n\n\n<li><strong>Pricing<\/strong>: Projected <strong>$800\u20111,200<\/strong> annual cost (30% discount to originator)<\/li>\n\n\n\n<li><strong>Peak Sales<\/strong>: <strong>$8\u201112\u202fmillion<\/strong> potential by 2028<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Company<\/th><th>Product<\/th><th>Region<\/th><th>Stage<\/th><th>Differentiation<\/th><\/tr><\/thead><tbody><tr><td><strong>Amgen<\/strong><\/td><td>Prolia (originator)<\/td><td>Global<\/td><td>Marketed<\/td><td>Brand leader<\/td><\/tr><tr><td><strong>BeiGene<\/strong><\/td><td>Prolia (China rights)<\/td><td>China<\/td><td>Marketed<\/td><td>Domestic distribution<\/td><\/tr><tr><td><strong>Boan Bio<\/strong><\/td><td><strong>BA6101<\/strong><\/td><td>Bolivia<\/td><td><strong>Approved<\/strong><\/td><td><strong>First Chinese biosimilar ex\u2011China<\/strong><\/td><\/tr><tr><td><strong>Sandoz<\/strong><\/td><td>Denosumab biosimilar<\/td><td>EU<\/td><td>Under review<\/td><td>Established player<\/td><\/tr><tr><td><strong>Samsung Bioepis<\/strong><\/td><td>Denosumab biosimilar<\/td><td>US<\/td><td>Phase\u202fIII<\/td><td>Late\u2011stage entrant<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Strategic Edge<\/strong>: Boan\u2019s <strong>first\u2011mover advantage<\/strong> in <strong>Latin America<\/strong> and <strong>emerging markets<\/strong> creates <strong>proof\u2011of\u2011concept<\/strong> for global regulatory acceptance.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-global-expansion-amp-financial-impact\">Global Expansion &amp; Financial Impact<\/h2>\n\n\n\n<p><strong>Filing Timeline<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>UK<\/strong>: Submission under review (MHRA); decision expected <strong>Q2\u202f2026<\/strong><\/li>\n\n\n\n<li><strong>EU<\/strong>: Planned <strong>Q3\u202f2026<\/strong> filing via <strong>decentralized procedure<\/strong><\/li>\n\n\n\n<li><strong>US<\/strong>: <strong>505(b)(2) pathway<\/strong> planned for <strong>2027<\/strong> (requires bridging studies)<\/li>\n\n\n\n<li><strong>Japan<\/strong>: <strong>PMDA consultation<\/strong> initiated; filing targeted <strong>2028<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Manufacturing<\/strong>: Boan\u2019s <strong>Yantai facility<\/strong> (capacity: <strong>2\u202fmillion units\/year<\/strong>) is <strong>EU GMP\u2011certified<\/strong>, enabling <strong>global supply<\/strong>.<\/p>\n\n\n\n<p><strong>Peak Sales Potential<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Ex\u2011China markets<\/strong>: <strong>$150\u2011200\u202fmillion<\/strong> by 2030 (assuming 5% global biosimilar share)<\/li>\n\n\n\n<li><strong>Total Portfolio Value<\/strong>: BA6101 could contribute <strong>\u00a52\u202fbillion<\/strong> (US$280\u202fmillion) to Boan\u2019s revenue base<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding BA6101\u2019s regulatory approvals, market penetration, and revenue forecasts. Actual results may differ materially due to competitive responses, pricing pressures, and regulatory review timelines.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2026011100008_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026011100008_c.\"><\/object><a id=\"wp-block-file--media-f2d1ec4e-8e3a-4b4b-bb85-532fee144169\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2026011100008_c.pdf\">2026011100008_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2026011100008_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-f2d1ec4e-8e3a-4b4b-bb85-532fee144169\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Shandong Boan Biotechnology Co., Ltd. (HKG: 6955) announced that BA6101, its biosimilar version of Amgen\u2019s&#8230;<\/p>\n","protected":false},"author":1,"featured_media":53733,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[43,220,1024,15],"class_list":["post-53729","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-biosimilars","tag-boan-biotechnology","tag-hkg-6955","tag-product-approvals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Boan Biosimilar Prolia Wins Bolivia Approval, Targets Global Markets - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shandong Boan Biotechnology Co., Ltd. (HKG: 6955) announced that BA6101, its biosimilar version of Amgen\u2019s Prolia (denosumab), received marketing approval from Bolivia\u2019s AGEMED (Agencia Estatal de Medicamentos y Tecnolog\u00edas en Salud). The 60mg injection for osteoporosis marks Boan\u2019s first regulatory approval in South America and advances its global expansion strategy, with filings already under review in the UK and planned for Europe, the US, and Japan.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=53729\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Boan Biosimilar Prolia Wins Bolivia Approval, Targets Global Markets\" \/>\n<meta property=\"og:description\" content=\"Shandong Boan Biotechnology Co., Ltd. (HKG: 6955) announced that BA6101, its biosimilar version of Amgen\u2019s Prolia (denosumab), received marketing approval from Bolivia\u2019s AGEMED (Agencia Estatal de Medicamentos y Tecnolog\u00edas en Salud). The 60mg injection for osteoporosis marks Boan\u2019s first regulatory approval in South America and advances its global expansion strategy, with filings already under review in the UK and planned for Europe, the US, and Japan.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=53729\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-12T06:31:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1202.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53729#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53729\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Boan Biosimilar Prolia Wins Bolivia Approval, Targets Global Markets\",\"datePublished\":\"2026-01-12T06:31:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53729\"},\"wordCount\":375,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53729#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/1202.webp\",\"keywords\":[\"Biosimilars\",\"Boan Biotechnology\",\"HKG: 6955\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53729#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53729\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=53729\",\"name\":\"Boan Biosimilar Prolia Wins Bolivia Approval, Targets Global Markets - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53729#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53729#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/1202.webp\",\"datePublished\":\"2026-01-12T06:31:37+00:00\",\"description\":\"Shandong Boan Biotechnology Co., Ltd. (HKG: 6955) announced that BA6101, its biosimilar version of Amgen\u2019s Prolia (denosumab), received marketing approval from Bolivia\u2019s AGEMED (Agencia Estatal de Medicamentos y Tecnolog\u00edas en Salud). The 60mg injection for osteoporosis marks Boan\u2019s first regulatory approval in South America and advances its global expansion strategy, with filings already under review in the UK and planned for Europe, the US, and Japan.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53729#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53729\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53729#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/1202.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/1202.webp\",\"width\":1080,\"height\":608,\"caption\":\"Boan Biosimilar Prolia Wins Bolivia Approval, Targets Global Markets\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53729#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Boan Biosimilar Prolia Wins Bolivia Approval, Targets Global Markets\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Boan Biosimilar Prolia Wins Bolivia Approval, Targets Global Markets - Insight, China&#039;s Pharmaceutical Industry","description":"Shandong Boan Biotechnology Co., Ltd. (HKG: 6955) announced that BA6101, its biosimilar version of Amgen\u2019s Prolia (denosumab), received marketing approval from Bolivia\u2019s AGEMED (Agencia Estatal de Medicamentos y Tecnolog\u00edas en Salud). The 60mg injection for osteoporosis marks Boan\u2019s first regulatory approval in South America and advances its global expansion strategy, with filings already under review in the UK and planned for Europe, the US, and Japan.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=53729","og_locale":"en_US","og_type":"article","og_title":"Boan Biosimilar Prolia Wins Bolivia Approval, Targets Global Markets","og_description":"Shandong Boan Biotechnology Co., Ltd. (HKG: 6955) announced that BA6101, its biosimilar version of Amgen\u2019s Prolia (denosumab), received marketing approval from Bolivia\u2019s AGEMED (Agencia Estatal de Medicamentos y Tecnolog\u00edas en Salud). The 60mg injection for osteoporosis marks Boan\u2019s first regulatory approval in South America and advances its global expansion strategy, with filings already under review in the UK and planned for Europe, the US, and Japan.","og_url":"https:\/\/flcube.com\/?p=53729","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-12T06:31:37+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1202.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=53729#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=53729"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Boan Biosimilar Prolia Wins Bolivia Approval, Targets Global Markets","datePublished":"2026-01-12T06:31:37+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=53729"},"wordCount":375,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=53729#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1202.webp","keywords":["Biosimilars","Boan Biotechnology","HKG: 6955","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=53729#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=53729","url":"https:\/\/flcube.com\/?p=53729","name":"Boan Biosimilar Prolia Wins Bolivia Approval, Targets Global Markets - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=53729#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=53729#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1202.webp","datePublished":"2026-01-12T06:31:37+00:00","description":"Shandong Boan Biotechnology Co., Ltd. (HKG: 6955) announced that BA6101, its biosimilar version of Amgen\u2019s Prolia (denosumab), received marketing approval from Bolivia\u2019s AGEMED (Agencia Estatal de Medicamentos y Tecnolog\u00edas en Salud). The 60mg injection for osteoporosis marks Boan\u2019s first regulatory approval in South America and advances its global expansion strategy, with filings already under review in the UK and planned for Europe, the US, and Japan.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=53729#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=53729"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=53729#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1202.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1202.webp","width":1080,"height":608,"caption":"Boan Biosimilar Prolia Wins Bolivia Approval, Targets Global Markets"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=53729#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Boan Biosimilar Prolia Wins Bolivia Approval, Targets Global Markets"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1202.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53729","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=53729"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53729\/revisions"}],"predecessor-version":[{"id":53734,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53729\/revisions\/53734"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/53733"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=53729"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=53729"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=53729"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}